MabCure Inc. (MBCI)
MabCure Inc. operates in the Medical - Pharmaceuticals industry of the Healthcare sector, headquartered in White Plains, NY, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $6,436. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of -2490.3%. Its beta of 7.88 implies it has historically moved more than the broad market.
MabCure Inc., a development stage company, engages in developing and commercializing its proprietary antibody technology for the early detection of cancer, and for the creation of specific therapeutics against cancer. It owns a proprietary technology for the generation of monoclonal antibodies against desired antigens, such as cancer markers. The company was formerly known as Smartec Holdings, Inc. and changed its name to MabCure Inc. in January 2008 to reflect its new business plan. MabCure Inc. was founded in 2006 and is based in White Plains, New York.
MabCure Inc. is most often compared with the following Healthcare names: